Drug Profile
AL 002
Alternative Names: AL 002; AL 002a; AL-002cLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator AbbVie; Alector
- Class Antibodies; Antidementias; Immunotherapies; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action TREM2 protein-stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Preclinical Neurodegenerative disorders
Most Recent Events
- 16 Jul 2023 Pharmacodynamics data from a preclinical study in Alzheimer’s disease presented at the Alzheimer's Association International Conference (AAIC-2023)
- 16 Jan 2023 Alector initiates a phase II trial for Alzheimer's disease (Early-stage disease, In adults, In elderly) in Spain (EudraCT2022-002987-57)
- 22 Apr 2022 Phase-II development is ongoing in the UK and Australia